JPMorgan raises target for Johnson & Johnson stock to USD 285

Published on 10/01/2026 at 11:27 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

JPMorgan keeps Neutral on Johnson & Johnson stock at USD 285. EUR 233.75 was 0.11 percent below EUR 234.00 on October 1, 2026.

Modern hospital operating room with robotic surgical arms positioned above a draped patient, surgeons in blue sterile gowns monitoring vital-sign and anatomy screens, bright overhead surgical lighting, stainless steel instrument trays in the foreground — Johnson und US4781601046 zeigen modernen Krankenhaus OP mit Robotik Chirurgie und medizinischen Bildschirmen, Illustration mit AI erstellt.

Johnson & Johnson (US4781601046) was trading at EUR 233.75 at Lang & Schwarz on October 1, 2026 at 11:17 a.m. CEST, with a minus 0.11 percent change versus the EUR 234.00 prior close. The latest analyst move came from JPMorgan, which raised its price target from USD 270.00 to USD 285.00 on September 29, 2026, while keeping a Neutral rating, according to Markets Insider.

JPMorgan lifts its target

The move puts JPMorgan's target USD 51.25 above the Lang & Schwarz price when comparing the two currencies separately. The target change itself was USD 15.00, or 5.56 percent, calculated against the previous USD 270.00 target.

JPMorgan's Neutral stance matters because the target increase did not come with a stronger rating. The research note described the company as a clean healthcare name with sustained growth, but also said that the favorable fundamentals were already reflected in the valuation, Markets Insider reported.

Quarterly figures beat consensus

In the second quarter of 2026, Johnson & Johnson reported revenue of USD 25.31 billion, up 6.60 percent from the same period a year earlier. Earnings per share came in at USD 2.90 versus USD 2.84 expected, a USD 0.06 beat, while fiscal 2026 earnings-per-share guidance stood at USD 11.60-11.75, according to MarketBeat.

The comparison shows why analysts are raising targets while preserving caution: revenue growth was positive, but the stock valuation and pressure on Stelara remain central issues for the earnings outlook. MarketBeat said 25 analysts had a Moderate Buy consensus and an average 12-month target of USD 274.13 on September 29, 2026, MarketBeat reported.

Results arrive October 13

Johnson & Johnson is scheduled to report third-quarter 2026 results before the market opens on October 13, 2026. The date is listed by MarketBeat, making the upcoming report the next dated test for the company's fiscal 2026 outlook.

Stock remains below its yearly high

The primary-exchange quote was USD 264.74 on the NYSE on September 30, 2026 at 4:00 p.m. ET, against a 52-week range of USD 182.94 to USD 281.07. The Lang & Schwarz price was EUR 233.75 on October 1, 2026 at 11:17 a.m. CEST, versus the EUR 234.00 prior close and a minus 0.11 percent daily change. The further course of trading is shown by the continuously updated real-time quote of Johnson & Johnson stock.